Pier Capital LLC Increases Stake in Certara, Inc. $CERT

Pier Capital LLC raised its position in Certara, Inc. (NASDAQ:CERT) by 13.1% in the 3rd quarter, Holdings Channel reports. The fund owned 754,600 shares of the company’s stock after acquiring an additional 87,178 shares during the period. Certara accounts for approximately 1.4% of Pier Capital LLC’s holdings, making the stock its 17th biggest position. Pier Capital LLC’s holdings in Certara were worth $9,221,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in CERT. Associated Banc Corp increased its stake in shares of Certara by 9.7% during the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock worth $146,000 after acquiring an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its position in Certara by 2.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after purchasing an additional 1,136 shares during the period. Versant Capital Management Inc lifted its position in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. boosted its holdings in Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares in the last quarter. Finally, Corient Private Wealth LLC increased its position in Certara by 11.1% during the 2nd quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock worth $144,000 after purchasing an additional 1,232 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $6.56 on Friday. The firm has a 50 day moving average of $8.02 and a 200-day moving average of $9.64. Certara, Inc. has a 12-month low of $6.04 and a 12-month high of $15.38. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -656.00 and a beta of 1.50.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same quarter in the prior year, the company earned $0.15 EPS. The business’s revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CERT shares. Rothschild & Co Redburn set a $10.00 target price on Certara in a research note on Friday, November 21st. Barclays restated an “equal weight” rating and issued a $8.00 price target on shares of Certara in a research note on Friday, March 6th. KeyCorp cut their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, January 8th. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 target price for the company. in a report on Friday, February 27th. Finally, Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Certara has an average rating of “Hold” and a consensus target price of $11.10.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.